UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
November 5, 2007
------------
CRUCELL NV
(Exact name of registrant as specified in its charter)
P.O. BOX 2048 ARCHIMEDESWEG 4 2333 CN LEIDEN THE NETHERLANDS
(Address of principal executive offices)
000-30962
(Commission File Number)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F:
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
DSM BIOLOGICS AND CRUCELL ANNOUNCE PER.C6(R)
TECHNOLOGY LICENSING AGREEMENT WITH RECEPTA BIOPHARMA S.A.
SITTARD/LEIDEN, THE NETHERLANDS, NOVEMBER 2, 2007 - DSM Biologics, a business
unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V.
(Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that they have
signed a non-exclusive PER.C6(R) technology research licensing agreement with
Brazilian-based Recepta Biopharma S.A. This agreement allows Recepta Biopharma
to use the PER.C6(R) technology to develop four antibodies it has licensed-in
from the Ludwig Institute for Cancer Research. Financial details were not
disclosed.
ABOUT PER.C6(R) TECHNOLOGY
Crucell's PER.C6(R) technology platform has been developed for the large-scale
manufacture of biopharmaceutical products such as recombinant proteins including
monoclonal antibodies. Compared to conventional production technologies, the
strengths of PER.C6(R) technology lie in its excellent safety profile,
scalability and productivity under serum-free culture conditions.
ABOUT CRUCELL
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology
company focused on research, development and worldwide marketing of vaccines and
antibodies that prevent and treat infectious diseases. Its vaccines are sold in
public and private markets worldwide. Crucell's core portfolio includes a
vaccine against hepatitis B, a fully-liquid vaccine against five important
childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell
also markets travel vaccines, such as the only oral anti-typhoid vaccine, an
oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the
market. The Company has a broad pipeline, with several products based on its
unique PER.C6(R) production technology in development. The Company licenses this
and other technologies to the biopharmaceutical industry. Important partners and
licensees include DSM Biologics, sanofi aventis, Novartis, Wyeth and Merck & Co.
Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in
Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a
1000 people. For more information, please visit www.crucell.com
ABOUT DSM BIOLOGICS
DSM Biologics, a business unit of DSM Pharmaceutical Products, is a global
provider of manufacturing technology and services to the biopharmaceutical
industry. In addition to offering world-class biopharmaceutical manufacturing
services, DSM Biologics has co-exclusive rights, along with Dutch biotech
company Crucell N.V., to license the high-producing PER.C6(R) human cell line as
a production platform for recombinant proteins and monoclonal antibodies. DSM
Biologics' FDA-approved facility in Groningen, The Netherlands, was established
in 1986 and has a strong track record in using a broad range of cell lines
(PER.C6(R), CHO, hybridoma, etc.) in biopharmaceutical manufacturing, and has a
wide range of experience using multiple manufacturing (batch, fed-batch and
continuous perfusion) and purification techniques. The combination of the
PER.C6(R) human cell line and DSM's manufacturing services provides companies
with a turn-key biologic manufacturing solution reducing cost, risk and time to
market. For more information, please visit www.dsmbiologics.com
ABOUT DSM
DSM is active worldwide in nutritional and pharma ingredients, performance
materials and industrial chemicals. The company develops, produces and sells
innovative products and services that help improve the quality of life. DSM's
products are used in a wide range of end-markets and applications, such as human
and animal nutrition and health, personal care, pharmaceuticals, automotive and
transport, coatings and paint, housing and electrics & electronics (E&E). DSM's
strategy, named Vision 2010 - Building on Strengths, focuses on accelerating
profitable and innovative growth of the company's specialties portfolio. The key
drivers of this strategy are market-driven growth and innovation plus an
increased presence in emerging economies. The group has annual sales of over
(euro)8 billion and employs some 22,000 people worldwide. DSM ranks among the
global leaders in many of its fields. The company is headquartered in the
Netherlands, with locations in Europe, Asia, Africa, Australia and the Americas.
More information about DSM can be found at www.dsm.com.
Forward-looking statements
This press release contains forward-looking statements that involve inherent
risks and uncertainties. These statements are based on current expectations,
estimates and projections of the management of DSM and Crucell and information
currently available to both companies. The statements involve certain risks and
uncertainties that are difficult to predict and therefore DSM and Crucell do not
guarantee that their expectations will be realized. Furthermore, DSM and Crucell
have no obligation to update the statements contained in this press release.
Crucell has identified certain important factors that may cause actual results
to differ materially from those contained in such forward-looking statements.
For information relating to these factors please refer to the Form 20-F, as
filed by Crucell with the U.S. Securities and Exchange Commission on June 13,
2007, and the section entitled "Risk Factors". Crucell prepares its financial
statements under generally accepted accounting principles in the United States
(US GAAP) and Europe (IFRS).
FOR FURTHER INFORMATION PLEASE CONTACT:
DSM PHARMACEUTICAL PRODUCTS CRUCELL N.V. MEDIA:
Karen King Barbara Mulder
President Director Corporate Communications
DSM Biologics Tel: +31-(0)71-519 7346
Tel: +1-973-257-8427 press@crucell.com
Karen.King@dsm.com
DSM BIOLOGICS INVESTORS/ANALYSTS:
Marcel Lubben Oya Yavuz
Vice President Director Investor Relations
Marketing, Sales & NBD Tel: +31-(0)71-519 7064
Tel: +31-(0)46-477 3343 ir@crucell.com
marcel-m.lubben@dsm.com
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
CRUCELL NV
-----------------------------------------
(Registrant)
November 5, 2007 /s/ LEON KRUIMER
- ------------------------ -----------------------------------------
(Date) Leon Kruimer
Chief Financial Officer